Pages that link to "Q43755968"
Jump to navigation
Jump to search
The following pages link to Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease (Q43755968):
Displaying 32 items.
- Comparison of [(15)O] H2O Positron Emission Tomography and Functional Magnetic Resonance Imaging in Activation Studies (Q26766509) (← links)
- Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease (Q30989943) (← links)
- Role of central angiotensin receptors in scopolamine-induced impairment in memory, cerebral blood flow, and cholinergic function. (Q34169364) (← links)
- Treatment effects in multiple cognitive domains in Alzheimer's disease: a two-year cohort study (Q34629649) (← links)
- Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis (Q34648742) (← links)
- Donepezil can improve daily activities and promote rehabilitation for severe Alzheimer's patients in long-term care health facilities (Q34789455) (← links)
- Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics (Q34965949) (← links)
- Neurovascular function in Alzheimer's disease patients and experimental models (Q35088223) (← links)
- Relation between medial temporal atrophy and functional brain activity during memory processing in Alzheimer's disease: a combined MRI and SPECT study (Q35469864) (← links)
- Differential effects of acetylcholinesterase inhibitors on clinical responses and cerebral blood flow changes in patients with Alzheimer's disease: a 12-month, randomized, and open-label trial (Q35631407) (← links)
- Effect of toki-shakuyaku-san on regional cerebral blood flow in patients with mild cognitive impairment and Alzheimer's disease (Q35796586) (← links)
- Donepezil in Alzheimer's disease: an evidence-based review of its impact on clinical and economic outcomes. (Q35876403) (← links)
- Changes in regional cerebral blood flow and functional connectivity in the cholinergic pathway associated with cognitive performance in subjects with mild Alzheimer's disease after 12-week donepezil treatment (Q35882869) (← links)
- Molecular neuroimaging in Alzheimer's disease (Q36045276) (← links)
- Toward the validation of functional neuroimaging as a potential biomarker for Alzheimer's disease: implications for drug development (Q36136747) (← links)
- Treating vascular risk factors and maintaining vascular health: is this the way towards successful cognitive ageing and preventing cognitive decline? (Q36388561) (← links)
- Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story (Q36475090) (← links)
- Functional neuroimaging in Alzheimer's disease (Q36587881) (← links)
- The validity of biomarkers as surrogate endpoints in Alzheimer's disease by means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLES). (Q37418999) (← links)
- Cerebral blood flow is an earlier indicator of perfusion abnormalities than cerebral blood volume in Alzheimer's disease (Q37695322) (← links)
- Evidence from functional neuroimaging of a compensatory prefrontal network in Alzheimer's disease. (Q38430049) (← links)
- Evaluation of treatment effects in Alzheimer's and other neurodegenerative diseases by MRI and MRS (Q41888068) (← links)
- Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation. (Q44251907) (← links)
- PET and SPECT investigations in Alzheimer's disease (Q44573184) (← links)
- A pilot study evaluating the efficacy and safety of rivastigmine in patients with mixed dementia (Q46349899) (← links)
- Quantitative analysis of the effects of donepezil on regional cerebral blood flow in Alzheimer's disease by using an automated program, 3DSRT. (Q46592838) (← links)
- Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease. (Q46622922) (← links)
- PET is better than perfusion SPECT for early diagnosis of Alzheimer's disease -- against (Q46800359) (← links)
- Cognitive evaluation of disease-modifying efficacy of donepezil in the APP23 mouse model for Alzheimer's disease (Q46896407) (← links)
- Beyond symptomatic effects: potential of donepezil as a neuroprotective agent and disease modifier in Alzheimer's disease. (Q48356126) (← links)
- Brain perfusion effects of cholinesterase inhibitors in Parkinson's disease with dementia. (Q48507834) (← links)
- Vascular Dysfunction in Alzheimer's Disease: A Prelude to the Pathological Process or a Consequence of It? (Q64986754) (← links)